Normal view MARC view ISBD view

Rituximab in Neuromyelitis Optica Spectrum Disorders: Why Not as First-Line Therapy.

Kim, Su-Hyun

Rituximab in Neuromyelitis Optica Spectrum Disorders: Why Not as First-Line Therapy. [electronic resource] - JAMA neurology 04 2017 - 482 p. digital

Publication Type: Journal Article; Comment

ISSN: 2168-6157

Standard No.: 10.1001/jamaneurol.2016.5933 doi

Subjects--Topical Terms:
Humans
Immunologic Factors
Neuromyelitis Optica
Rituximab

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)